Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves
surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where …

Lung cancer is worldwide the most common malignancy. Standard of care treatments for
early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant …

Lung cancer is the most common malignant tumor with the highest mortality, and about 84%
are non-small cell lung cancer (NSCLC). However, only a small proportion of patients with …

Lung cancer is the leading cause of cancer-related deaths worldwide and in China (1).
According to the National Cancer Center of China, there were more than 815,000 new cases …

Objective Progress in neoadjuvant therapy for resectable nonsmall cell lung cancer (NSCLC
1) has been stagnant. There have been great achievements in immunotherapy for advanced …

Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with
resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However …

Background With a 5% improvement in 5-year overall survival achieved with current
neoadjuvant or adjuvant chemotherapy, new treatments for resectable non-small cell lung …

Lung cancer is the leading cause of cancer-related death worldwide and in China (1).
According to the statistics of the National Cancer Center of China, there were 733,300 new …

Non-small cell lung cancer (NSCLC) remains a major cause of morbidity and mortality
worldwide. One-third of NSCLC patients present with surgically resectable, non-metastatic …